JP2005505579A - アンタゴニスト - Google Patents

アンタゴニスト Download PDF

Info

Publication number
JP2005505579A
JP2005505579A JP2003530818A JP2003530818A JP2005505579A JP 2005505579 A JP2005505579 A JP 2005505579A JP 2003530818 A JP2003530818 A JP 2003530818A JP 2003530818 A JP2003530818 A JP 2003530818A JP 2005505579 A JP2005505579 A JP 2005505579A
Authority
JP
Japan
Prior art keywords
insulin
seq
growth factor
amino acid
factor receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505579A5 (enExample
Inventor
レヌーカ ピルートラ，
オルガ デドヴァ，
アーサー， ジェイ． ブルーム，
ニール， アイ． ゴールドスタイン，
レニー ブリセット，
ピンガー ワン，
ハオ リュー，
クー−チュアン シャオ，
マイケル レニック，
ポール フレッチャー，
Original Assignee
ノボ・ノルデイスク・エー／エス
ディージーアイ バイオテクノロジーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボ・ノルデイスク・エー／エス, ディージーアイ バイオテクノロジーズ filed Critical ノボ・ノルデイスク・エー／エス
Publication of JP2005505579A publication Critical patent/JP2005505579A/ja
Publication of JP2005505579A5 publication Critical patent/JP2005505579A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003530818A 2001-09-24 2002-09-24 アンタゴニスト Pending JP2005505579A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/962,756 US6875741B2 (en) 1998-09-02 2001-09-24 Insulin and IGF-1 receptor agonists and antagonists
PCT/US2002/030412 WO2003027246A2 (en) 2001-09-24 2002-09-24 Antagonists

Publications (2)

Publication Number Publication Date
JP2005505579A true JP2005505579A (ja) 2005-02-24
JP2005505579A5 JP2005505579A5 (enExample) 2006-01-05

Family

ID=25506313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003530818A Pending JP2005505579A (ja) 2001-09-24 2002-09-24 アンタゴニスト
JP2003569654A Pending JP2005517741A (ja) 2001-09-24 2002-09-24 インシュリン及びｉｇｆ−１レセプターのアゴニスト及びアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003569654A Pending JP2005517741A (ja) 2001-09-24 2002-09-24 インシュリン及びｉｇｆ−１レセプターのアゴニスト及びアンタゴニスト

Country Status (6)

Country Link
US (1) US6875741B2 (enExample)
EP (2) EP1496935A4 (enExample)
JP (2) JP2005505579A (enExample)
AU (2) AU2002341834A1 (enExample)
CA (2) CA2459999A1 (enExample)
WO (2) WO2003027246A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501664A (ja) * 2015-10-23 2019-01-24 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6521738B2 (en) * 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
AU2003205830A1 (en) 2002-01-23 2003-09-02 Mohamed Raafat El-Gewely Molecular libraries
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) * 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
AU2003228525A1 (en) * 2002-04-22 2003-11-03 Greenville Hospital System Multimeric ligands with enhanced stability
JP4563171B2 (ja) * 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8334135B2 (en) * 2002-07-31 2012-12-18 Yves Saint Laurent Parfums Stem cells from adipose tissue, and differentiated cells from said cells
US20040176291A1 (en) * 2002-09-24 2004-09-09 Elly Nedivi Methods and compositions for soluble CPG15
JP2007535895A (ja) * 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
US20050187175A1 (en) * 2003-09-30 2005-08-25 Elly Nedivi Methods and compositions for CPG15-2
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US7781393B2 (en) 2004-02-25 2010-08-24 Dana-Farber Cancer Institute, Inc. Methods for inhibiting tumor cell growth
DK1755660T3 (da) * 2004-05-07 2010-07-19 Univ North Carolina Fremgangsmåde til forbedring eller hæmning af insulin-lignende vækstfaktor-I
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
US20100298213A1 (en) * 2004-08-20 2010-11-25 Novo Nordisk A/S Pharmaceutically Active Insulin Receptor-Modulating Molecules
WO2006052468A2 (en) * 2004-10-27 2006-05-18 University Of Denver Adrenocorticotropic hormone analogs and related methods
WO2006045710A2 (en) * 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
EP1828249B1 (en) * 2004-12-03 2010-12-29 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
NZ561648A (en) * 2005-04-15 2009-11-27 Schering Corp Methods and composition of IGF1R inhibitors for treating or preventing cancer
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
PL2100618T3 (pl) * 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
US7622438B1 (en) 2005-07-18 2009-11-24 Acologix, Inc. Protein formulation for promoting hard tissue formation
JP2009511446A (ja) * 2005-10-05 2009-03-19 ノボ・ノルデイスク・エー／エス インスリンレセプターアンタゴニストと、関連した組成物、使用及び方法
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
WO2007095113A2 (en) * 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EP2468766B1 (en) 2006-06-22 2014-09-17 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
WO2008005992A2 (en) * 2006-07-06 2008-01-10 Molecular Logix, Inc. Dominant negative ligand drug discovery system
WO2008133961A2 (en) 2007-04-24 2008-11-06 Antyra Inc. Igf-1r binding proteins and antagonists
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA201500156A3 (ru) 2008-01-03 2017-09-29 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
EP2376099A4 (en) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
US8481485B2 (en) 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
EP2438090B1 (en) * 2009-05-28 2016-07-06 The United States Government as Represented by the Department of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
US20120178693A1 (en) * 2009-08-28 2012-07-12 Bayer Healthcare Llc Cofactors for Thrombin Activation of Factor VII and Uses Thereof
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
US9244073B2 (en) 2011-02-25 2016-01-26 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CA2838824A1 (en) * 2011-06-10 2012-12-13 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
RU2015106333A (ru) 2012-08-31 2016-10-27 Зэ Юниверсити Оф Норз Каролина Эт Чапел Хилл Моноклональные антитела для стимуляции или ингибирования инсулиноподобного фактора роста 1 (igf-1)
CN104981251B (zh) 2012-09-26 2018-03-20 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CA2959629C (en) * 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN107001441A (zh) 2014-09-24 2017-08-01 印第安纳大学研究及科技有限公司 脂质化的基于酰胺的胰岛素前药
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
MY205459A (en) * 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
WO2021146657A1 (en) * 2020-01-16 2021-07-22 The Translational Genomics Research Institute Methods of identifying synthetic molecular binding agents
WO2022020246A1 (en) * 2020-07-23 2022-01-27 The Scripps Research Institute Insulin receptor-mediated enhancement of gene transfer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0378671B1 (en) * 1988-06-30 1997-03-12 City Of Hope Insulinomimetic and insulin receptor binding site peptides
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
DE4432943A1 (de) 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
RU2078769C1 (ru) 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
WO1997007827A1 (en) 1995-08-22 1997-03-06 Thomas Jefferson University Gab1, A Grb2 BINDING PROTEIN, AND COMPOSITIONS FOR MAKING AND METHODS OF USING THE SAME
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
WO1997046682A2 (en) 1996-06-07 1997-12-11 Genetics Institute, Inc. Polynucleotides from human adult pbmc encoding secreted proteins
JP2002512685A (ja) * 1997-01-15 2002-04-23 テリック・インコーポレイテッド インスリン受容体活性のモジュレーター
JP2001525339A (ja) 1997-11-27 2001-12-11 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション Ｉｇｆ受容体に対するアゴニストおよびアンタゴニストの設計方法
CA2356109C (en) 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2001072771A2 (en) * 2000-03-29 2001-10-04 Dgi Biotechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6010017698, Ｊ． Ａｍ． Ｓｏｃ． Ｎｅｐｈｒｏｌ． （２０００） ｖｏｌ．１１， ｎｏ．１１， ｐ．２０２７−２０３５ *
JPN6010017699, Ｂｉｏｐｏｌｙｍｅｒｓ （２０００） ｖｏｌ．５５， ｎｏ．４， ｐ．３４７−３５６ *
JPN6010017701, ＥＭＢＯ Ｊ． （２０００） ｖｏｌ．１９， ｎｏ．７， ｐ．１５２５−１５３３ *
JPN6010017704, Ｇｅｎｅ （１９９３） ｖｏｌ．１２８， ｎｏ．１， ｐ．３７−４２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501664A (ja) * 2015-10-23 2019-01-24 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用
JP7174627B2 (ja) 2015-10-23 2022-11-17 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用

Also Published As

Publication number Publication date
JP2005517741A (ja) 2005-06-16
WO2003070747A3 (en) 2004-11-11
CA2459999A1 (en) 2003-04-03
AU2002341834A1 (en) 2003-04-07
WO2003070747A2 (en) 2003-08-28
WO2003027246A3 (en) 2003-07-31
EP1432433A2 (en) 2004-06-30
AU2002366384A8 (en) 2003-09-09
US20030195147A1 (en) 2003-10-16
EP1496935A2 (en) 2005-01-19
WO2003027246A2 (en) 2003-04-03
AU2002366384A1 (en) 2003-09-09
CA2460055A1 (en) 2003-08-28
US6875741B2 (en) 2005-04-05
EP1432433A4 (en) 2006-08-30
EP1496935A4 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
JP2005505579A (ja) アンタゴニスト
US7173005B2 (en) Insulin and IGF-1 receptor agonists and antagonists
US20090192072A1 (en) Insulin and IGF-1 Receptor Agonists and Antagonists
JP3971108B2 (ja) インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
ES2329220T3 (es) Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
EP1383793B1 (en) Insulin and igf-1 receptor agonists and antagonists
WO2000023469A2 (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
ES2301547T3 (es) Tratamiento de trastornos del cartilago.
JP2001520748A (ja) Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
JP2007537711A (ja) Ｉｇｆ結合タンパク質
GB2471693A (en) Parathyroid hormone related protein antagonists
WO2001036446A2 (en) Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases
US7148193B2 (en) Compounds that bind to growth hormone receptor
Bathgate et al. Relaxin family peptide receptors in GtoPdb v. 2021.3
EP1506972A1 (en) Insulin-like growth factor (IGF) I mutant variants
AU2007202546A1 (en) IGF antagonist peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100917

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110125